High quality evidence indicates that aspirin is effective in reducing colorectal polyps; and numerous
epidemiological studies point towards an ability to prevent colorectal cancer. However the role of Aspirin as an
adjuvant agent in patients with established cancers remains to be defined. Recently a nested case-control study
within the Nurses Health cohort suggested that the initiation of Aspirin after the diagnosis of colon cancer reduced
overall colorectal cancer specific mortality. Although this data is supportive of Aspirin’s biological activity in this
disease and possible role in adjuvant therapy, it needs to be confirmed in a randomized prospective trial.